Atlas Trials

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Clinical trial NCT06874933 · RECRUITING

Trial details

NCT number
NCT06874933
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HR+/HER2- Breast Cancer
Start date
2025-05-04
Primary completion
2027-04-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.